This was the consensus amongst top African and American health AI experts who participated in a webinar (https://apo-opa.info/3O1seIV) about the impact of GenAI on healthcare. The webinar was hosted by Vantage Health Technology (www.VantageHealth.Tech) – part of BroadReach Group, a social enterprise focussed on health equity globally. Through Vantage, the company has provided AI-led health-tech support to multiple public healthcare systems and diseases including in Africa and the USA for close to a decade.
“The fundamental issue in healthcare, whether you are in Sub-Saharan Africa, Western Europe, or the USA, is that demand outstrips supply in terms of health services, doctors, nurses, and medications. In Sub-Saharan Africa, for instance, there are 0.2 doctors per 1000 people,” explains Dr John Sargent, co-founder of the BroadReach Group (www.BroadReachCorporation.com).
He says we are trying to deliver on an antiquated model of “sick care”, where there is a certain ratio of doctors to patients. “We need to change this paradigm to be more effective by matching the supply and demand sides of our health systems in new digital ways.” Dr Sargent, who is a Harvard alumni and former World Economic Forum Social Entrepreneur of the Year, says that while GenAI has the potential to revolutionise how healthcare supply and demand are balanced, it is not the be-all-and-end-all of health tech. “The aim is not to get distracted by a shiny new toy – we need to put the patient first by protecting privacy and training our models against bias. We must always remember that technology is just a tool in service of patient care and supporting the healthcare workforce to improve health outcomes.”
Using GenAI to tackle specific diseases such as HIV and AIDS
Jaya Plmanabhan (https://apo-opa.info/43wY6KX), chief scientist at innovation consultancy Newfire Global (https://apo-opa.info/44UF3eR) who trains health AI models for a living, says he is particularly excited about how large language models could be trained to revolutionise virtual expertise on diseases such as HIV and AIDS. “We call these ‘Role Specific Domain Models’ and they have the potential to be programmed to know everything about a particular disease, to better guide healthcare professionals on how to treat patients. This is a tremendously exciting prospect in the mission to end new HIV infections by 2030.”
These Private Language Models (PLMs) become oracles on a subject and are especially useful in helping solve hard problems in HIV management, such as loss to follow-up – a term for patients who drop off treatment. “Trying to find patients is critical to ensure that they don’t become resistant to drugs due to skipping doses. We can make our outreach much more engaging through conversational messages in their mother tongue and this can help us get people back into the clinic and back into care,” explains Ruan Viljoen (https://apo-opa.info/3XZcdHV), Chief Technology Officer of the BroadReach Group.
Start with the problem, not the solution
“There is a quote that says we should fall in love with the problem, not the solution, which in this case is AI,” says Viljoen. “I believe the biggest challenge is still health inequity - healthcare access can vary depending on race, location, or age.”
Viljoen said GenAI can help solve practical problems, such as frontline healthcare workers being overburdened and not having enough time. “What are the repetitive, administrative tasks that are stealing their time? For instance, GenAI can help nurses with automated note-taking in patient interviews, relieving an administrative burden. The goal is not to replace the role but to free up their time for value-added work.”
One of the greatest uses of AI in health is to help healthcare workers focus on the next best action. “We can use large datasets and extract insights to help healthcare workers, delivered via easy-to-digest and secure messaging like emails or text messages. This is nothing new – we’ve done this in some form for nearly a decade using our AI-enabled platform, Vantage (https://apo-opa.info/3qJ1Tax). What I’m most excited about, is how we can augment the quality of the interactions to bring together human and artificial intelligence.”
Heeding the risks and creating guardrails
Vedantha Singh (https://apo-opa.info/3OglE2l), an AI ethics in healthcare researcher and virologist from the University of Cape Town, said the top ethical considerations for AI in healthcare are privacy, accuracy, and fairness. She urged at all AI systems should start with guardrails and ethics within their foundational design.
“There is a perception that there are no regulations for the use of AI in healthcare, but to assume we are operating in the wild west is not true. International bodies are sharing guidelines and regulation is slowly evolving – including in Africa. Egypt, Rwanda and Mauritius already have strong AI policies,” says Singh. This includes an emphasis on human labour not being completely replaced and giving patients agency over how their data is used.
Singh says that companies must embed ethical guardrails – aka ‘guardrails by design’ in their health products from the start. Plmanabhan adds that GenAI can reduce costs and personalise care, but it must be used carefully. “For example, if the data is biased, the model will be biased. GenAI can also be used to create fake patient profiles to commit fraud.” Unbiased, quality data which complies to regulations such as HIPAA and POPIA or GDPR must be prioritised.
Plmanabhan emphasises the importance of patients giving informed consent, knowing how GenAI is being used on their data. “We need to stay committed to immovable core principles - we cannot compromise on the human in the middle of it all.”
Reaching the hardest to reach patients
Viljoen says GenAI is not just improving healthcare for urban patients. Those in deeply rural areas could benefit too.
“Internet connectivity and satellite communication are becoming more ubiquitous. A few things provide hope: Big cloud providers are providing more ‘edge computing’ for rural areas, the mobile phone is becoming a very powerful computer in the pockets of people all around the world, and small rural clinics can use smaller GenAI models which require smaller amounts of data and computing power– they don’t need to use ChatGPT,” says Viljoen.
Plmanabhan explains that there are secondary GenAI models that can function offline. The primary models are always online, with and secondary models sending information back to the primary model once it is back online.
Hope for an equitable healthcare revolution
GenAI can increase affordable and equitable healthcare through the automation of routine tasks. To create a world where more equitable healthcare exists, it is critical to establish strong partnerships between donors, policy makers, researchers, and healthcare implementers.
Viljoen concludes, “We need to be experiment rapidly with AI, and deploy cautiously. It’s an incredible time to work in health technology and to see how we can use it to at last achieve health equity.”
Distributed by APO Group on behalf of BroadReach Group.
Media queries:
Jennifer Kingwill
Jennifer.Kingwill@accenture.com
About BroadReach Group and Vantage Health Technologies:
BroadReach Group is a group of social impact businesses focused on harnessing innovation and technology to empower human action. Since 2003 BroadReach Group has worked in over 30 countries to support governments, international NGOs, public and private sector to improve health outcomes for their populations. In South Africa alone, during the COVID-19 period BroadReach supported two South African provinces to oversee and manage their COVID-19 outbreaks over a population of 15 million people.
Vantage Health Technologies – a BroadReach Group company, created the Vantage platform which uses Artificial Intelligence (AI) and analytics to provide health leaders and workers with personalised data insights and step-by-step next best actions to guide impact at scale. The combination AI and human action makes true health equity.
For more information visit www.BroadReachCorporation.com or www.VantageHealth.Tech
This website uses cookies.